Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

NCT07496567

RecruitingPhase 2, Phase 3

Sponsor: EyeBiotech Ltd.

Conditions: Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration

Interventions: Tiespectus, Aflibercept

Countries: United States, Brazil, Colombia, Czechia, France, Hungary, Portugal, Spain

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.

Eligibility overview

Sex: ALL

Age: 50 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
The main inclusion criteria include but are not limited to the following:

* Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye)
* The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment

The main exclusion criteria include but are not limited to the following

* Has uncontrolled blood pressure at screening
* History of any prior macular laser photocoagulation in the study eye
* History of uveitis in either eye
* History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study
* Has uncontrolled glaucoma in the study eye
* Active retinal disease other than the condition under investigation in the study eye
* Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye
Locations (63)
  • Gilbert, Arizona, United States
  • Encino, California, United States
  • Mountain View, California, United States
  • Colorado Springs, Colorado, United States
  • Denver, Colorado, United States
  • Pueblo, Colorado, United States
  • Danbury, Connecticut, United States
  • Manchester, Connecticut, United States
  • Waterford, Connecticut, United States
  • Fort Myers, Florida, United States
  • Orlando, Florida, United States
  • Sarasota, Florida, United States
  • Winter Haven, Florida, United States
  • Joliet, Illinois, United States
  • Lemont, Illinois, United States
  • West Des Moines, Iowa, United States
  • Lenexa, Kansas, United States
  • Louisville, Kentucky, United States
  • Portland, Maine, United States
  • Hagerstown, Maryland, United States
  • Springfield, Massachusetts, United States
  • Edina, Minnesota, United States
  • Bloomfield, New Jersey, United States
  • Great Neck, New York, United States
  • Rochester, New York, United States
  • Asheville, North Carolina, United States
  • Cary, North Carolina, United States
  • Hickory, North Carolina, United States
  • Wake Forest, North Carolina, United States
  • Salem, Oregon, United States
  • + 33 more on CT.gov